HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles

Haffar, Omar K.; Smithgall, Molly D.; Morán, Patricia; Travis, Bruce; Zarling, Joyce M.; Hu, Shiu‐Lok

doi:10.1016/0042-6822(91)90978-k

Cited by 34 publications

(27 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gag-only particles of the type described have a number of uses as 'particle carriers', for example of the HIV env protein, to produce non-replicating vaccine candidates (Haffar et al, 1991). We suggest that if this technology comes into widespread use for the production of recombinant vaccines, the use of constructs similar to Pr42 be encouraged as they would prevent the possible transduction of RNA to recipient ceils.…”

Section: Discussionmentioning

confidence: 99%

“…The ability of gag gene products to self-assemble following expression has been established for a number of retroviruses, bovine (Rasmussen et al, 1990), feline (Morikawa et al, 1991), human Karacostas et al, 1989;Overton et al, 1989;Hu et al, 1990;Luo et al, 1990;Shioda & Shibuta, 1990;Smith et al, 1990;Haffar et al, 1991;Hoshikawa et al, 1991;Royer et al, 1991;Mergener et al, 1992) and simian immunodeficiency viruses (Delchambre et al, 1989). However, the boundaries of the gag sequences necessary for particle formation have not been systematically determined.…”

Section: Discussionmentioning

confidence: 99%

“…In this way, the enzymatic functions necessary for virus infectivity (the protease, reverse transcriptase, RNase H and integrase) are incorporated into the budding particle. When expressed alone in a number of eukaryotic expression systems, Pr55 produces virus-like particles very similar to the early budding immature particles seen in HIV-infected cells Karacostas et al, 1989;Overton et al, 1989;Hu et al, 1990;Luo et al, 1990;Shioda & Shibuta, 1990;Smith et al, 1990;Haffar et al, 1991 ;Hoshikawa et al, 1991 ;Royer et al, 1991 ;Mergener et al, 1992). The ability of similar core antigens from other retroviruses to self-assemble into particle structures is now well documented (Delchambre et al, 1989;Rasmussen et al, 1990;Morikawa et al, 1991).…”

Section: Introductionmentioning

confidence: 95%

See 2 more Smart Citations

Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation

Jowett

Hockley

Nermut

et al. 1992

Journal of General Virology

113

138

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation

Jowett

Hockley

Nermut

et al. 1992

Journal of General Virology

113

138

View full text Add to dashboard Cite

“…Sci. USA 93 (1996) 11861 like core but are composed exclusively of Gag (MA, CA, NC, and p6) and Env (gp4l and gp120) proteins (19). These pseudovirions package HIV-1 gag RNA and, as we have shown recently (26), translocate this RNA into the nucleus of an infected cell in a manner similar to the behavior of HIV-1 preintegration complexes.…”

Section: Methodsmentioning

confidence: 88%

Critical role of reverse transcriptase in the inhibitory mechanism of CNI-H0294 on HIV-1 nuclear translocation.

Попов¹,

Dubrovsky²,

Lee³

et al. 1996

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

HIV-1 replication requires the translocation of viral genome into the nucleus of a target cell. We recently reported the synthesis of an arylene bis(methyl ketone) compound (CNI-H0294) that inhibits nuclear targeting of the HIV-1 genome and thus HIV-1 replication in monocyte cultures. Here we demonstrate that CNI-H0294 inhibits nuclear targeting of HIV-1-derived preintegration complexes by inactivating the nuclear localization sequence of the HIV-1 matrix antigen in a reaction that absolutely requires reverse transcriptase. This drug/reverse transcriptase interaction defines the specificity of its antiviral effect and is most likely mediated by the pyrimidine side-chain of CNI-H0294. After binding to reverse transcriptase, the carbonyl groups of CNI-H0294 react with the nuclear localization sequence of matrix antigen and prevent its binding to karyopherin a, the cellular receptor for nuclear localization sequences that carries proteins into the nucleus. Our results provide a basis for the development of a novel class of compounds that inhibit nuclear translocation and that can, in principle, be modified to target specific infectious agents.

show abstract

“…Such a simpler HIV-1 is fundamentally different from vector-or DNA-expressed HIV-1 structural proteins, which cannot replicate in the vaccine recipient (18)(19)(20)(21) (26). Assembly of Gag, Pol, and Env proteins into virions appears to proceed in the absence of accessory proteins (18)(19)(20)(21)(22).…”

mentioning

confidence: 99%

A proposal for a new approach to a preventive vaccine against human immunodeficiency virus type 1.

Temin¹

1993

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Human immunodeficiency virus type 1 (HIV-1) is a more complex retrovirus, coding for several accessory proteins in addition to the structural proteins (Gag, Pol, and Env) that are found in all retroviruses. More complex retroviruses have not been isolated from birds, and simpler retroviruses have not been isolated from humans. However, the proviruses of many endogenous simpler retroviruses are present in the human genome. These observations suggest that humans can mount a successful protective response against simpler retroviruses, whereas birds cannot. Thus, humans might be able to mount a successful protective response to infection with a simpler HIV-1. As a model, a simpler bovine leukemia virus which is capable of replicating has been constructed; a simpler HIV-1 could be constructed in a similar fashion. I suggest that such a simpler HIV-1 would be a safe and effective vaccine against HIV-1.

show abstract

HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles

Cited by 34 publications

References 22 publications

Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation

Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation

Critical role of reverse transcriptase in the inhibitory mechanism of CNI-H0294 on HIV-1 nuclear translocation.

A proposal for a new approach to a preventive vaccine against human immunodeficiency virus type 1.

Contact Info

Product

Resources

About